Marco Capobianco

7.2k total citations · 1 hit paper
83 papers, 2.2k citations indexed

About

Marco Capobianco is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology. According to data from OpenAlex, Marco Capobianco has authored 83 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Pathology and Forensic Medicine, 25 papers in Neurology and 25 papers in Oncology. Recurrent topics in Marco Capobianco's work include Multiple Sclerosis Research Studies (59 papers), Peripheral Neuropathies and Disorders (21 papers) and Polyomavirus and related diseases (18 papers). Marco Capobianco is often cited by papers focused on Multiple Sclerosis Research Studies (59 papers), Peripheral Neuropathies and Disorders (21 papers) and Polyomavirus and related diseases (18 papers). Marco Capobianco collaborates with scholars based in Italy, United States and Germany. Marco Capobianco's co-authors include Antonio Bertolotto, Simona Malucchi, Fabiana Marnetto, Arianna Sala, Francesca Gilli, Alessia Di Sapio, Paola Valentino, Marzia Caldano, Lucia Moiola and Letizia Granieri and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Neurology.

In The Last Decade

Marco Capobianco

79 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

2021 296 citations Maria Pia Sormani, Nicola De Rossi et al. Annals of Neurology profile →

Peers

Marco Capobianco

PFM

NEURO

ONCOL

IMMUN

RHEUM

Mónica Marta United Kingdom

Harold Koendgen Switzerland

A Wajgt Poland

Bhupendra Khatri United States

Martin Duddy United Kingdom

Verena Grummel Germany

Ilijas Jelčić Switzerland

W. H. Stuart United States

Carol L. Vanderlugt United States

Alexandros Tselis United States

Mónica Marta United Kingdom

Marco Capobianco

1.0k ×0.6

PFM

368 ×0.5

NEURO

487 ×0.8

ONCOL

761 ×1.4

IMMUN

266 ×0.5

RHEUM

Citations per year, relative to Marco Capobianco Marco Capobianco (= 1×) peers Mónica Marta

Countries citing papers authored by Marco Capobianco

Since Specialization

Citations

This map shows the geographic impact of Marco Capobianco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Capobianco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Capobianco more than expected).

Fields of papers citing papers by Marco Capobianco

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Capobianco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Capobianco. The network helps show where Marco Capobianco may publish in the future.

Co-authorship network of co-authors of Marco Capobianco

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Capobianco. A scholar is included among the top collaborators of Marco Capobianco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Capobianco. Marco Capobianco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Capobianco, Marco, Marius Ringelstein, Marco Aurélio Lana–Peixoto, et al.. (2023). Characterization of Disease Severity and Stability in NMOSD: A Global Clinical Record Review with Patient Interviews. Neurology and Therapy. 12(2). 635–650. 4 indexed citations

Min, Ju‐Hong, Marco Capobianco, Marco Aurélio Lana–Peixoto, et al.. (2023). Understanding Treatment Decisions in Neuromyelitis Optica Spectrum Disorder: A Global Clinical Record Review with Patient Interviews. Neurology and Therapy. 12(2). 619–633. 7 indexed citations

Malentacchi, Maria, Simona Malucchi, Francesca Sperli, et al.. (2023). Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study. Neurology and Therapy. 12(4). 1375–1383. 5 indexed citations

Montarolo, Francesca, Serena Martire, Francesco Chiara, et al.. (2022). NURR1 ‐deficient mice have age‐ and sex‐specific behavioral phenotypes. Journal of Neuroscience Research. 100(9). 1747–1754. 11 indexed citations

Montarolo, Francesca, Serena Martire, Fabiana Marnetto, et al.. (2022). The Selective Agonist for Sphingosine-1-Phosphate Receptors Siponimod Increases the Expression Level of NR4A Genes in Microglia Cell Line. Current Issues in Molecular Biology. 44(3). 1247–1256. 7 indexed citations

Martire, Serena, et al.. (2022). The impact of pre-freezing storage time and temperature on gene expression of blood collected in EDTA tubes. Molecular Biology Reports. 49(6). 4709–4718. 3 indexed citations

Sormani, Maria Pia, Nicola De Rossi, Irene Schiavetti, et al.. (2021). Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of Neurology. 89(4). 780–789. 296 indexed citations breakdown →

Sormani, Maria Pia, Nicola De Rossi, Irene Schiavetti, et al.. (2021). Different disease modifying therapies can increase or decrease Covid-19 severity in Multiple Sclerosis (2021). Neurology. 96(15_supplement). 4 indexed citations

Bruijstens, Arlette L., Christian Lechner, Lorraine Flet‐Berliac, et al.. (2020). E.U. paediatric MOG consortium consensus: Part 1 – Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. European Journal of Paediatric Neurology. 29. 2–13. 86 indexed citations

10.

Bertolotto, Antonio, et al.. (2020). Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing–Remitting Multiple Sclerosis Patients. Neurology and Therapy. 9(2). 197–203. 11 indexed citations

11.

Annovazzi, Pietro, Marco Capobianco, Lucia Moiola, et al.. (2016). Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. Journal of Neurology. 263(9). 1727–1735. 40 indexed citations

12.

Prosperini, Luca, Pietro Annovazzi, Marco Capobianco, et al.. (2015). Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. Multiple Sclerosis Journal. 21(13). 1713–1722. 19 indexed citations

13.

Perga, Simona, A. Giuliano Albo, Sara Falvo, et al.. (2015). Vitamin D Binding Protein Isoforms and Apolipoprotein E in Cerebrospinal Fluid as Prognostic Biomarkers of Multiple Sclerosis. PLoS ONE. 10(6). e0129291–e0129291. 27 indexed citations

14.

Marnetto, Fabiana, Letizia Granieri, Paola Valentino, et al.. (2014). CD19 mRNA quantification improves rituximab treatment-to-target approach: A proof of concept study. Journal of Neuroimmunology. 277(1-2). 127–133. 5 indexed citations

15.

Malucchi, Simona, Francesca Gilli, Marzia Caldano, et al.. (2008). Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology. 70(13_part_2). 1119–1127. 71 indexed citations

16.

Capobianco, Marco, Simona Malucchi, Stefano Ulisciani, et al.. (2008). Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis. Neurological Sciences. 29(3). 185–187. 9 indexed citations

17.

Capobianco, Marco, Simona Malucchi, Alessia Di Sapio, et al.. (2007). Variable responses to rituximab treatment in neuromyelitis optica (Devic’s disease). Neurological Sciences. 28(4). 209–211. 55 indexed citations

18.

Dovio, Andrea, L. Saba, A Termine, et al.. (2006). High-dose glucocorticoids increase serum levels of soluble IL-6 receptor α and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. European Journal of Endocrinology. 154(5). 745–751. 36 indexed citations

19.

Bertolotto, Antonio, Simona Malucchi, Eva Milano, et al.. (2000). Interferon β neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology. 48(2). 95–100. 77 indexed citations

20.

Bertolotto, Antonio, Marco Capobianco, Simona Malucchi, et al.. (1999). Transforming growth factor β1 (TGFβ1) mRNA level correlates with magnetic resonance imaging disease activity in Multiple Sclerosis patients. Neuroscience Letters. 263(1). 21–24. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact